I am currently working in these roles. T-Neuro is using T cells to track and treat neurodegenerative diseases, such as Alzheimer's Disease.

Zocere, Inc. (formerly Tyrosine Pharmaceuticals, Inc.) is a company whose mission is to develop a therapeutic agent to reduce brain damage, most notably in stroke patients. The novel peptide sequence is a derivative of a naturally occurring striatal-enriched tyrosine phosphatase (STEP). The peptide is delivered by intravenous injection after an acute ischemic stroke, providing significant protection against ischemic brain injury.

Company name changed from Myriad Pharmaceuticals, Inc to Myrexis, Inc. Responsible for a business areas, including corporate and business development (including facilities management and IR/PR), clinical affairs, biostatistics and data management, IT, research services, QA/QC, and commercial operations

Member of the spin off team to spin Myriad Pharmaceuticals from the parent Myriad Genetics. In addition to commercial operations, assumed responsibilities for corporate and business development (included facilities management and IR/PR), biostatistics and data management, research services, QA/QC, IT and clinical affairs

Responsible for commercial operations for Myriad Genetics' wholly owned subsidiary Myriad Pharmaceuticals, Inc. (MPI)

Managed the company's business development and commercial organization including the launch of PLETAL and partnership and launch of ABILIFY

Business Unit director for Mid Atlantic and SouthEast regions. Included sales and managed care teams.

Responsible for Sales and Marketing for anti-infectives globally. Commercial responsibilities in Europe and UK for broader portfolio management.